Skip to main content
Clinical Trials/NL-OMON53449
NL-OMON53449
Recruiting
Not Applicable

Integration of Whole-Genome Sequencing profiles and Immune Status in cancer - a molecular profiling protocol to broaden the view on drug targets and immune contexture in patients with melanoma and pancreatic cancer - SONATA

Amsterdam UMC0 sites180 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
maligne neoplasmata pancreas
Sponsor
Amsterdam UMC
Enrollment
180
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational invasive

Investigators

Sponsor
Amsterdam UMC

Eligibility Criteria

Inclusion Criteria

  • 1\. Diagnosis of locally advanced or metastatic cutaneous/mucosal melanoma or
  • pancreatic cancer, meeting the following characteristics:
  • a. Melanoma
  • i. Patients with histologically proven locally advanced or metastatic melanoma
  • (stage IV), with intrinsic or acquired resistance to treatment with immune
  • checkpoint inhibition (anti\-PD1 antibody \+/\- ipilimumab)
  • ii. Patients with locoregional or distant recurrence either during, or within 3
  • months after completion or discontinuation of (neo)adjuvant anti\-PD1\-based
  • immunotherapy for stage III melanoma.
  • b. Pancreatic cancer

Exclusion Criteria

  • Patients with metastatic or locally advanced lesions which are not considered
  • to be technically and/or safely biopsied

Outcomes

Primary Outcomes

Not specified

Similar Trials